MRC/BHF Heart Protection Study - Reply

MRC/BHF Heart Protection Study - Reply

Manylion Llyfryddiaeth
Prif Awduron:	Collins, R, Armitage, J, Parish, S, Sleight, P, Peto, R, Col, M
Fformat:	Journal article
Cyhoeddwyd:	2002

Eitemau Tebyg

Comments on the MRC/BHF Heart Protection Study - Authors' reply
gan: Collins, R, et al.
Cyhoeddwyd: (2003)

The MRC/BHF Heart Protection Study: preliminary results.
gan: Collins, R, et al.
Cyhoeddwyd: (2002)

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial
gan: Collins, R, et al.
Cyhoeddwyd: (2002)

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
gan: Collins, R, et al.
Cyhoeddwyd: (2003)

Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
gan: Parish, S, et al.
Cyhoeddwyd: (2012)

MRC/BHF Heart Protection Study.
gan: Vaughan, C, et al.
Cyhoeddwyd: (2002)

N-BNP and vascular disease among 20,536 patients in the MRC/BHF Heart Protection Study
gan: Emberson, J, et al.
Cyhoeddwyd: (2005)

Heart Protection Study - Reply
gan: Collins, R, et al.
Cyhoeddwyd: (2003)

New analyses of Heart Protection Study - Reply
gan: Collins, R, et al.
Cyhoeddwyd: (2004)

N-terminal pro-B-type natriuretic peptide and vascular disease among 20,536 patients in the MRC/BHF heart protection study
gan: Emberson, J, et al.
Cyhoeddwyd: (2005)

MRC/BHF heart protection study (HPS): Mortality, cancer incidence and major vascular events during 4 years post-trial follow-up of HPS
gan: Bulbulia, R, et al.
Cyhoeddwyd: (2007)

Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials.
gan: Armitage, J, et al.
Cyhoeddwyd: (2000)

N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study.
gan: Emberson, JR, et al.
Cyhoeddwyd: (2007)

Randomized trial of cholesterol-lowering and antioxidant vitamins in 5,000 women at high-risk of coronary heart disease
gan: Collins, R, et al.
Cyhoeddwyd: (2002)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
gan: Heart Protection Study Collaborative Group
Cyhoeddwyd: (2002)

AFTER ISIS-3 - REPLY
gan: Collins, R, et al.
Cyhoeddwyd: (1992)

C-reactive protein in the Heart Protection Study - Authors' reply
gan: Emberson, J, et al.
Cyhoeddwyd: (2011)

C-reactive protein in the Heart Protection Study Reply
gan: Emberson, J, et al.
Cyhoeddwyd: (2011)

Randomized trial of cholesterol-lowering and antioxidant vitamins in 7,000 high-risk individuals with LDL cholesterol below 120 mg/dl
gan: Collins, R, et al.
Cyhoeddwyd: (2002)

Effects of cholesterol-lowering therapy and antioxidant vitamin supplementation on the risk of stroke
gan: Collins, R, et al.
Cyhoeddwyd: (2002)

Randomized trial of cholesterol-lowering, and of antioxidant vitamins, in 6,000 people with diabetes mellitus
gan: Collins, R, et al.
Cyhoeddwyd: (2002)

ISIS-4 - REPLY
gan: Collins, R, et al.
Cyhoeddwyd: (1995)

Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
gan: Collins, R, et al.
Cyhoeddwyd: (2004)

MRC BHFHeart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience
gan: Meade, T, et al.
Cyhoeddwyd: (1999)

ISIS-3 - REPLY
gan: Collins, R, et al.
Cyhoeddwyd: (1991)

Genetic variation in lipid response to statin therapy in 18,705 participants in the heart protection study
gan: Hopewell, J, et al.
Cyhoeddwyd: (2011)

In search of genetic precision - Reply
gan: Keaveny, B, et al.
Cyhoeddwyd: (2003)

ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials.
gan: Collins, R, et al.
Cyhoeddwyd: (1993)

LOW CHOLESTEROL AND CORONARY HEART-DISEASE - REPLY
gan: Chen, Z, et al.
Cyhoeddwyd: (1991)

Economic evaluation of the Heart Protection Study
gan: Briggs, A, et al.
Cyhoeddwyd: (2003)

No Impact of KIF6 Genotype on Vascular Risk or Statin Benefit in the Heart Protection Study
gan: Hopewell, J, et al.
Cyhoeddwyd: (2009)

Assessing the impact sensitivity of explosives using the BHF-12A equipment
gan: Rădeanu Cristian, et al.
Cyhoeddwyd: (2020-01-01)

In reply
gan: Armitage, J, et al.
Cyhoeddwyd: (2010)

Regarding "Does simvastatin save lives; If so, when and in whom?" - Reply
gan: Bulbulia, R, et al.
Cyhoeddwyd: (2008)

Lipoprotein(a) Genetic Variants Associated With Risk of Atherothrombotic Disease in 14,465 Participants From the Heart Protection Study
gan: Hopewell, J, et al.
Cyhoeddwyd: (2010)

MRC2020: improvements to Ximdisp and the MRC image-processing programs
gan: J. M. Short, et al.
Cyhoeddwyd: (2023-09-01)

Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study.
gan: Hopewell, J, et al.
Cyhoeddwyd: (2011)

The authors reply
gan: Collins, R, et al.
Cyhoeddwyd: (2009)

The MRC spine stabilization trial
gan: Wilson-MacDonald, J, et al.
Cyhoeddwyd: (2008)

Failure Investigation of Blank Holder Force (BHF) Control in The Outside Bracket For Front Seat
gan: Rofan Yulian Romansyah, et al.
Cyhoeddwyd: (2023-06-01)